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BONE GROWTH FOLLOWING DEMINERALIZED BONE MATRIX 
IMPLANTATION REQUIRES ANGIOGENESIS 
STEPHANIE LAM 
ABSTRACT 
 Angiogenesis is required for endochondral ossification during development and 
fracture healing; however the exact mechanisms and temporal relationship between the 
two processes remains unclear. In this study, we utilize an in vivo model of endochondral 
ossification in mice by implanting demineralized bone matrix (DBM) proximal to the 
femur to induce ectopic bone formation. TNP-470, a drug known to be anti-angiogenic, 
was used to inhibit vascularization during the time course of de novo bone formation in 
order to define the role of angiogenesis during the chondrogenic phase of endochondral 
bone formation. Day 2, day 8, and day 16 post-surgery were selected time points to 
represent pre-chondrogenic, chondrogenic, and bone mineralization stages, respectively. 
Plain x-ray and micro-CT analysis showed that inhibition of angiogenesis led to 
decreased mineralized tissue formation. Inhibited angiogenesis was confirmed with qRT-
PCR. Most striking, however, is that while stem cells are recruited and committed to the 
chondrogenic lineage, subsequent chondrogenesis failed to progress based on the failure 
of Sox5 and Sox6 expression, which directs chondrocyte commitment. This expands the 
role for angiogenesis to a much earlier stage than currently thought and places the 
necessity of angiogenesis very early in the endochondral ossification process. 
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INTRODUCTION 
 
Each year, approximately 6 million people in the United States experience bone 
fractures, 300,000 of which inefficiently heal or are unable to fully recover from injury 
(“Physical Fields”, 2002, para. 1). Bone fractures are attributable to phenomenon ranging 
anywhere from rigorous sports to vitamin deficiencies, hormonal imbalances, and normal 
aging (Lips, 2001). Bone fractures heal via endochondral ossification, which utilizes a 
cartilage model, and intramembranous ossification, which does not require cartilage. 
While both processes are involved in bone formation during development and in 
repairing bones after injury, endochondral ossification is required for axial and 
appendicular long and short bone formation (Mescher, 2010, p.129). Thus, thoroughly 
understanding the molecular mechanisms of endochondral ossification is critical to 
gaining insight into bone development and into the development of therapies for fracture 
healing. 
 
Endochondral Ossificiation  
Endochondral ossification is responsible for the development of most bones and 
begins with hyaline cartilage that is gradually replaced by bone. Hyaline cartilage mainly 
consists of type II collagen, but type VI collagen and type IX collagen are also present. In 
addition to its vital role in endochondral ossification, hyaline cartilage can be found in the 
joints, nose, bronchi, trachea, larynx, and ventral ends of the ribs (Mescher, 2010, p. 
114).  
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The endochondral ossification process starts with mesenchymal stem cells that 
condense to form cartilage. While markers specific to mesenchymal stem cells are poorly 
understood, transcription factors such as sex determining region Y (SRY)-box 2 (Sox2) 
and nanog homeobox (Nanog) have been suggested to be specifically expressed in all 
stem cells. Thus, they can be used as a means to measure mesenchymal stem cell 
recruitment (Park et al., 2012). 
SRY-box 9 (Sox9) is a transcription factor that is considered to be the earliest 
marker of chondrogenesis. Sox9 expression initiates stem cell commitment to the 
chondrocyte lineage (Kondo et al., 2013). Further, Sox9 activation leads to the activation 
of other chondrogenic transcription factors, SRY-box 5 (Sox5) and SRY-box 6 (Sox6) 
that, together, regulate the progression of chondrocyte differentiation. There is, however, 
redundancy between Sox5 and Sox6; expression of just one of these transcription factors 
was enough to avoid severe skeletal developmental abnormalities. Yet, Sox9 remains 
absolutely necessary for chondrogenesis, as inhibition of Sox9 has been shown to inhibit 
pre-cartilage condensation and all subsequent skeletal mechanisms (Akiyama & 
Lefebvre, 2011).  
The commitment of stem cells to chondrocytes leads to condensation, a stage in 
which mesenchymal cells condense into clusters that will eventually fully differentiate 
into chondrocytes. Neural cadherin (N-cadherin) and neural cell adhesion molecule 1 
(Ncam1) are two genes particularly critical to the condensation process; N-CADHERIN 
is responsible for initiating condensation, while NCAM1 is vital to the maintenance of 
condensation (Gilbert, 2000). Condensation of mesenchymal cells leads to 
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chondrogenesis, or cartilage formation, by chondrocytes at the epiphyseal plate (Mackie, 
2008). 
Collagen type II alpha 1 (Col2a1) is a gene for type II collagen and is considered 
one of the earliest chondrogenesis markers (Leung et al., 2011). Aggrecan (Acan) is 
downstream of Col2a1 in the chondrogenic process (Weber et al., 2013) and codes for 
cartilage proteoglycan (Han & Lefebvre, 2008). As ossification begins, the cartilage 
model is invaded by a mixture of cells (Mackie, 2008). A bone collar is formed by 
osteoblasts of the perichondrium and plays a role in preventing the transport of oxygen 
and nutrients to the underlying cartilage, which leads to the resorption of cartilage and, 
ultimately, programed cell death. Chondrocytes produce alkaline phosphatase and 
hypertrophy, causing the enlargement of lacunae, compression of the matrix, and 
calcification of the matrix (Mescher, 2010, p.129) (Figure 1). Collagen type X alpha 1 
(Col10a1) codes for these hypertrophic chondrocytes (Smits et al., 2001). Vascularization 
of the tissue occurs through perforations in the bone collar. Osteoprogenitors come into 
the bone via these vessels and differentiate into osteoblasts, which produce woven bone 
over the calcified cartilage matrix. The woven bone eventually remodels into compact 
bone, and ultimately, the last of the mineralized cartilage matrix is replaced by bone 
(Mescher, 2010, p.130). 
A second mechanism by which fracture healing may occur is intramembranous 
ossification. In intramembranous ossification, cells of the mesenchymal condensation 
layer differentiate into osteoblasts that lay down an osteoid matrix; calcification ensues, 
causing encapsulation of some osteoblasts that eventually become osteocytes. Then, the 
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connective tissue is vascularized, some mesenchymal cells differentiate into bone 
marrow, and the ossification centers radially expand until they fuse with one another.  
Figure 1. Light micrograph of 
endochondral ossification. Arrowheads 
point to vascularization, oc denotes 
osteoclasts, arrows point to deposition of 
bone matrix, and cm denotes cartilage 
matrix remnants. (A) Epiphyseal growth 
plate. (B) Chondrocyte proliferation.(C) 
Hypertrophic chondrocytes. (D) 
Enlargement of lacunae. Figure taken 
from Mackie et al., 2008. 
 
Intramembranous ossification primarily 
takes place during the condensation of 
embryonic mesenchymal tissue and is 
responsible for the formation of the 
skull, the mandible, and the maxilla 
(Mescher, 2010, p.129). 
 
Mechanism of Bone Formation 
Bone formation is induced by 
growth factors known as bone 
morphogenetic proteins (BMPs). Bone 
morphogenetic protein 2 (BMP2), a 
ligand of the transforming growth factor 
ß (TGF-ß) superfamily, acts by binding 
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to BMP receptor type II (BMPRII), a serine-threonine receptor kinase. It then recruits and 
phosphorylates BMP receptor type I  (BMPRI). In turn, BMPRI phosphorylates SMAD1, 
SMAD5, and SMAD8, which complex with co-SMAD4 to undergo translocation to the 
nucleus, where they interact with transcription factors and regulate gene expression. An 
example of such a transcription factor is Runt-related transcription factor 2 (Runx2), 
which is involved with osteoblast differentiation (Chen et al., 2004). An antagonist to 
BMP signaling is NOGGIN (Gobeske et al., 2009), which has been shown to decrease 
both osteoblast action and differentiation (Devlin et al., 2003). BMP2 is essential for 
bone repair and formation. A study on mice showed that those unable to produce BMP2 
experienced spontaneous fractures and were unable to recover from them, despite other 
osteogenic genes being present (Tsuji et al., 2006). In fact, when a mouse model lacking 
proper expression of BMPRII was created by truncation of the C-terminal of Bmpr2, the 
mice showed smaller embryos, delayed bone mineralization, and slower skeletal 
development overall (Yang et al., 2010). 
There are two main types of cells associated with bone formation: 
osteoblasts/osteocytes and osteoclasts. Osteoblasts arise from the differentiation of 
multipotent mesenchymal stem cells, and their primary function is the formation of new 
bone (Harada & Rodan, 2003). Osterix (Lee et al., 2003) and Osteocalcin (Ducy & 
Karsenty, 1995) are both markers for osteoblasts. Osteoblasts that become embedded 
within their own secretions and mineralized bone become terminally differentiated and 
are called osteocytes. Their roles are involved in bone networks for exchange of nutrients 
and bone turnover (Aarden et al., 1994). Dentin matrix protein 1 (Dmp1) is a gene that is 
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expressed by osteocytes of lamellar and woven bone (Kashima et al., 2013). On the other 
hand, bone resorption is the function of osteoclasts, which are derived from monocytes 
(Fujikawa et al., 1996). Tartrate-resistant acid phosphatase 5b (Trap5b) is a marker 
whose expression parallels the number of osteoclasts present (Henriksen et al., 2007).  
The first type of bone tissue that appears in both development and fracture repair 
is woven bone, which appears as random collagen fibers and is low in mineral content. 
Woven bone is eventually replaced by lamellar bone containing multiple sheets of 
calcified matrix or lamellae. These lamellae are organized around a canal containing 
loose connective tissue, vascularization, and nerves called an osteon, creating the 
haversian system. Each lamella contains type I collagen fibers that are important for the 
strength and durability of compact bone. Bone remodeling is a process in which bone 
formation and resorption occur in a coupled manner and is a continuous, homeostatic 
process that replaces old bone with new bone (Mescher, 2010, p.125).  
 
Vascularization in Endochondral Ossification: Clues in Bone Healing 
Vascular endothelial growth factor (VEGF) is a master regulator of hematopoiesis 
and blood vessel development and is thus crucial to angiogenesis (Gerber et al., 2002). 
VEGF ligands, five of which have been identified, bind to one of three tyrosine kinase 
VEGF receptors (VEGFR) that have been identified: VEGFR-1, VEGFR-2, and VEGFR-
3. VEGFR-2 is responsible for endothelial cell growth, and the ligand VEGF-A has been 
found to play a critical role in normal vascular development. When activated by 
extracellular VEGF-A binding, VEGFR-2 dimerizes and undergoes auto-phosphorylation 
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of its intracellular tyrosine residues. Intracellular signaling leads to eventual hydrolysis of 
phosphatidylinositol 4,5-bisphosphate by phospholipase C-gamma and formation of 
diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 binds to receptors on the 
endoplasmic reticulum to cause release of intracellular Ca2+ stores, which along with 
DAG, activates protein kinase C (PKC). PKC activates the Raf-MEK-ERK pathway, a 
signaling cascade that ultimately results in increased transcription of endothelial genes, 
and consequently, proliferation of endothelial cells. Endothelial cells are the epithelial 
cells of blood vessels. Other VEGF-A and VEGFR-2 signaling pathways are essential to 
endothelial cell survival, permeability, and migration (Holmes et al., 2007).  
Current anti-angiogenic drugs include tyrosine kinase inhibitors and Fumagillin 
(Ellis & Hicklin, 2008). TNP-470 is a Fumagillin analog that inhibits VEGF (De Bandt et 
al., 2000) synthesis by irreversibly binding to and inactivating methionine 
aminopeptidase-2 (METAP-2), which causes arrest of the G1 phase of the endothelial cell 
cycle (“NCI Drug Dictionary”, n.d., para. 1). The specific mechanism by which 
endothelial cell growth interruption occurs is still under study, though it is currently 
believed that TNP-470 covalently binds to the METAP-2 active site’s catalytic 231His and 
inhibits the early steps of noncanonical Wnt pathway (Hines et al., 2010). 
Vascularization has been found to be a critical component of the bone healing 
process. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in rats have been 
shown to both delay and restrict the complete healing of femoral bone fractures, 
particularly by delayed maturation of callus that was observed in the analysis of histology 
and mechanical testing (Altman et al., 1995). NSAIDs act via inhibition of the 
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cyclooxygenase pathway to reduce prostaglandin release. Prostaglandins are known to 
cause vasodilation, and thus increase blood flow, to an area of stress where inflammation 
occurs. Such evidence supports the claim that vascularization plays a pivotal role in bone 
repair (Wheeler & Batt, 2005). 
Vascularization has also been shown to significantly increase in areas of bone 
injury. A study of dogs undergoing lengthening of the tibia at the proximal metaphysis 
showed, by quantitative technetium scintigraphy, a ten-fold increase in blood flow 
compared to the control at the distraction site. This study not only suggests that blood 
flow is crucial to bone disturbances but also proposes distraction osteogenesis as a means 
of improving bone healing by promoting vascularization (Aronson, 1994). In addition, 
Dr. Tomlinson and his colleagues created adult rat forelimb stress fractures using a 
mechanical loading process and showed that when Fumagillin was used to block 
angiogenesis, there was diminished vascularization and woven bone formation. Whether 
blood in the vascularization of fractured bone carries essential mineralization components 
or skeletal stem cells, or both, is a topic still under study today (Tomlinson et al., 2012). 
The necessity of angiogenesis in bone formation is further supported by findings 
of a positive correlation between VEGF and up-regulation of BMP2 expression in 
endothelial cells. When bovine and human endothelial cells were stimulated with 
recombinant human VEGF, BMP2 mRNA expression increased by 2 to 3 times after just 
24-48 hours post-stimulation. It was thus concluded that VEGF is crucial not only to 
angiogenesis but also to osteogenesis, suggesting a relationship between the two 
processes (Bouletreau et al., 2002). As anticipated, another study used VEGF antagonist 
	  	   9 
SFLT1 to show a notable decrease in BMP2-induced bone formation from muscle-
derived stem cells (Peng et al., 2005). 
Though angiogenesis has been shown to be critical in both the healing and 
development of bone, a clearer understanding of when angiogenesis plays a role in 
endochondral ossification is needed. It is has been known that vascularization brings 
osteoprogenitors into the cartilage matrix so that mineralization may take place (Mescher, 
2010, p. 130). But more recently, there is evidence of angiogenesis playing a key function 
in mesenchyme condensation during limb development, as it has been shown that the 
vascular patterning surrounding mesenchymal condensations undergo substantial 
rearrangement (Eshkar-Oren et al., 2009). 
 
Bone Grafts & Demineralized Bone Matrix 
Current methods of bone repair include the implementation of a variety of bone 
grafts. Osteoconductive materials include allograft bone and calcium sulfates or 
phosphates, which serve as a scaffold that recruits an ingrowth of osteoblasts and 
vascularization at the site of implantation (Bauer & Muschler, 2000). On the other hand, 
osteoinductive grafts function by attracting mesenchymal stem cells to its location, where 
they differentiate into bone cells to form bone. An example of this is demineralized bone 
matrix (DBM), a putty-like material that is used in bone repair.  
DBM is prepared commercially by harvesting and processing human soft tissue 
cortical bone into small particles. The bone particles are then demineralized in an agent 
such as hydrochloric acid and washed to create DBM powder. To finalize the process, the 
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DBM powder is combined with a denatured collagen solution to produce material of a 
putty consistency. DBM’s bone formation characteristics are attributed to BMP2 activity, 
which has been found to increase osteoinductive potential and promote osteogenic 
differentiation of mesenchymal stem cells; however, the exact mechanism by which 
DBM causes bone growth is still unclear (Pietrzak et al., 2005). DBM is readily available 
and often used in the clinical setting for periodontal and orthopedic cases (Maddox et al., 
2000). 
Since BMP2 has been demonstrated to play a necessary role in bone repair, its 
osteoinductive properties have been proposed for therapeutic uses to generate cartilage 
and bone (Wozney & Rosen, 1998). A synthetic peptide of BMP2 that was administered 
in rats using an alginate gel showed that BMP2 was capable of not only inducing ectopic 
bone formation but also accelerating bone repair in fractures (Saito et al., 2005). Thus, a 
recombinant human bone morphogenetic protein 2 (rhBMP-2) was produced and further 
tested through implantation in rat bone defects. This provided further support for the 
healing potential of BMP2 via induction of local endochondral bone formation (Yasko et 
al., 1992). Clinical testing showed improved surgical outcome with the use of rhBMP-2, 
ranging from decreased blood loss to shorter use of operating room time. As a result, 
rhBMP-2 was FDA-approved for human use in the orthopedic setting, such as for fracture 
healing (Khan & Lane, 2004). rhBMP2, among other recombinant human BMPs, is often 
administered using a collagen matrix as a carrier (Sharma et al., 2012). Common 
examples of collagen matrix vehicles are collagen sponges (Geiger et al., 2003) and 
DBM (Pietrzak et al., 2006). 
	  	   11 
Angiogenesis Mechanism in Skeletal Biology 
 There is clear evidence that a link exists between angiogenesis and bone 
formation, as shown by studies such as Gerber’s discovery of a positive correlation 
between VEGFR and BMP2 expression in endothelial cells that were stimulated with 
VEGFR (Bouletreau et al., 2002) and Tomlinson’s findings of diminished bone formation 
in fracture healing post-administration of an anti-angiogenic agent (Tomlinson et al., 
2013). In prior studies from our laboratory using a model of distraction osteogenesis to 
induce new bone formation, endothelial cells and smooth muscle cells in new vessels that 
formed in the surrounding muscle of the bone regenerate were shown to be the primary 
source of BMP2 production (Matsubara et al., 2012). Despite the prevalence of claims 
regarding angiogenesis to be a critical component in the bone formation process, little is 
known of the exact mechanism by which angiogenesis supports endochondral bone 
formation and the role it plays in stem cell recruitment and cartilage development . 
Manipulating angiogenesis using TNP-470 in an in vivo model indicative of bone 
formation, via DBM, allowed us to more closely observe the role of angiogenesis in 
endochondral ossification. In turn, we identified the requirement for angiogenesis 
considerably earlier in endochondral ossification. A better understanding of this 
mechanism will provide additional insight into physiological bone development and 
improve current therapies for fractures. 
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SPECIFIC AIMS 
 
 We hypothesize that angiogenesis is needed to support endochondral ossification 
in vivo. The main objective of this study is to gain a clearer understanding of the 
mechanism of angiogenesis in bone development, and in order to do so, we will: 
• Develop an in vivo model for de novo bone formation, which will take form in the 
implantation of DBM proximal to the femur via survival surgeries in mice. 
• Utilize an anti-angiogenic agent, specifically TNP-470, to manipulate 
vascularization of the bone formation model. 
• Conduct the experiment at critical time points of bone formation: day 2 for 
analysis of the initial stages of bone development, day 8 for investigation during 
the cartilaginous stages of endochondral ossification, and day 16 for the 
evaluation of mineralization. 
• Examine bone mineralization using x-rays and micro-computed tomography 
(micro-CT) analysis. 
• Uncover the mechanism by which angiogenesis occurs using a multitude of 
quantitative real-time polymerase chain reaction (qRT-PCR) primers 
representative of the key steps of endochondral ossification. 
• Discuss a possible mechanism for angiogenesis in endochondral ossification. 
We hope these studies will shed light on the mechanism by which angiogenesis 
specifically occurs in endochondral ossification, a topic that is currently unclear and has 
not been extensively studied in the past. 
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METHODS 
 
Animals & Surgery 
All animal studies were approved by the Institutional Animal Care and Use 
Committee at Boston University. The mice were housed under standard conditions. Mice 
of strain B6,129S7-Rag1tm1/MOM/J aged 10 to 13 weeks from The Jackson Laboratory 
were utilized in this study. The mice underwent surgery in which 50 mg of GRAFTON® 
DBM Putty was implanted bilaterally and proximal to the femur. During the first 36 
hours of post-operative care, both experimental and control mice were subcutaneously 
injected three times with 0.1 mL of Buprenex® as pain medication and once with 0.01 
mL of Baytril® as antibiotics. The mice were euthanized at three time points, day 2, 8, 
and 16 post-surgery. Five experimental animals were enrolled for each time point and 
subjected to TNP-470 injections. Control animals did not receive injections (n=4-7 per 
time point). A second set of animals were enrolled to serve as day 0 and did not receive 
surgery (n=5).  
 
TNP-470, Angiogenesis Inhibitor 
TNP-470 was obtained from EMD Chemicals, Inc., and a 10% stock solution was 
created by dissolving 10 mg of TNP-470 with 100 µL of ethanol. The working solution to 
be injected into the animals was diluted with phosphate buffered saline (PBS) to 5 
mg/mL. The first dose of TNP-470 (25 mg/kg) was injected in each mouse 
subcutaneously, approximately three hours post-surgery. Each consecutive dose was 
administered approximately 24 hours after the previous dose until the appropriate 
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experimental time point was reached. The mice were not injected with TNP-470 on the 
day of harvest. 
 
Harvest & X-rays 
On the day of harvest, the mice were euthanized via carbon dioxide inhalation 
followed by cervical dislocation. X-rays were then promptly taken of the left and right 
femur using the Faxitron MX-20 Specimen Radiography System, at a setting of 30 kV for 
40 seconds, with Kodak BioMax XAR Scientific Imaging Film.  
The DBM implant proximal to the left femur was dissected for mRNA analysis, 
and the tissues were snap-frozen in liquid nitrogen immediately after harvest and stored 
at -80°C. The skin from the right thigh was removed, leaving the muscle, DBM implant, 
and femur intact for Micro-CT analysis followed by histological preparation. For these 
samples, the tissues were first fixed in 4% paraformaldehyde (PFA) at 4°C for one week 
and then stored in 1X PBS at 4°C until use for the analysis. 
 
Micro-CT Analysis 
 Sequential micro-CT analysis was performed on three day 8 control samples, five 
day 8 experimental samples, five day 16 control samples, and five day 16 experimental 
samples using the SCANCO Medical µCT 40 Scanner. The scans were taken at a voltage 
of 70 kVp with a current of 114 µA at medium resolution. The integration time was 200 
ms, and a conical tube size of 20.5 mm was used. This analysis provided not only a 
visualization of the DBM implants surrounding the femur but also allowed for the 
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quantification of bone volume of the DBM implants. Analysis of animals from the day 2 
time point was not carried out because previous studies have shown that mineralization 
was unable to be detected at this time point (unpublished data). 
 
RNA Extraction 
RNA extraction was performed by tissue dissociation and chemical extraction of 
the DBM implants with the Qiagen Tissue Lyser II®. Each tissue sample was placed in a 
separate 0.2 mL tube with 0.75 mL Qiazol® Lysis Reagent and snap frozen in liquid 
nitrogen. A Qiagen stainless steel bead 5 mm in diameter was placed in each tube with 
the frozen sample and lysed in the Qiagen Tissue Lyser II® for approximately 3 minutes, 
or until the DBM implant was fully ground and thawed. The pink solution was then 
transferred to a new 2-mL tube, and 1 mL Qiazol® Lysis Reagent was added to each 
tube. The samples were then left on ice for at least 2 minutes before adding 0.2 mL 
chloroform obtained from Sigma-Aldrich®. The samples were vortexed, left on ice for 2 
minutes, and then vortexed thoroughly again. They were followed with centrifugation for 
15 minutes at 4°C and 14000 rpm. 
Approximately 0.75 mL of the resulting aqueous phase of each tube was 
transferred to a new Eppendorf Tube®, and an equal volume of isopropanol from Sigma-
Aldrich® was added. Each tube was inverted several times to turn the liquid from cloudy 
to clear and centrifuged for 30 minutes at 4°C and 14000 rpm.  
The supernatant was removed again, and the pellet was washed with 0.5 mL of 
70% ethanol from Sigma-Aldrich®, then centrifuged for 5 minutes at 4°C and 14000 
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rpm. Ethanol washing of the sample was repeated once more. The ethanol was finally 
removed, and the tubes were left open for approximately 30 minutes so that each pellet 
could dry. The dry pellets were then dissolved in 0.03 to 0.1 mL RNase-free water, 
preferably 0.1 mL depending on the size of the pellet, by pipetting up and down. The 
resulting extracted RNA was stored at -80°C. 
The integrity of the extracted RNA was analyzed using gel imaging and 
spectrophotometry. One µL of each sample was loaded onto a 1% gel, made with 
UltraPure™ agarose from Invitrogen and GelStar™ Nucleic Acid Gel Stain from Lonza 
Group, along with 2 µL of 6X Agarose Gel Loading Dye from Boston BioProducts 
diluted with 7 µL of RNase-free water. The appearance of bright bands on the gel 
confirmed the presence of intact RNA. Detection by spectrophotometer of a ratio of 
absorbance at 260 nm to absorbance at 280 nm in the range of 1.8 to 2.1 is desired to 
show that the RNA is of acceptable quality. 
 
cDNA Production 
 RNase-free water was added to 2 µg of the previously extracted RNA to produce 
a total volume of 10.4 µL in a 0.2-mL PCR tube. The TaqMan® Reverse Transcription 
Reagents kit from Applied Biosystems® was utilized, and a mixture of the following 
reagents and enzymes was produced: MgCl2 solution, dNTP Mix, 10X RT Buffer, 
Random Hexamers, RNase Inhibitor, and TaqMan® Reverse Transcriptase. 19.6 µL of 
this mixture was added to each sample to bring the total volume of the PCR tube to 30 
µL. The samples were then placed in an Eppendorf Mastercycler® Personal thermal 
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cycler to undergo PCR at the following settings: 25°C for 10 minutes, 37°C for 60 
minutes, 95°C for 5 minutes, and finally, a 4°C hold. RNase free water was used to make 
a 1:25 dilution of the resulting cDNA, which was stored at -20°C. 
 
Table 1. qRT-PCR 
Primers. Primers and 
their respective catalog 
numbers. 
  
	  	   18 
qRT-PCR 
 qRT-PCR was carried out using 10 µL TaqMan® Universal PCR Master Mix 
from Applied Biosystems® and 1 µL TaqMan® Gene Expression Assays from Applied 
Biosystems® for 9 µL of each sample. A list of primers used in this study can be found in 
Table 1. A 96-well qPCR plate was used, and doublets of each sample were run. RNase-
free water was used in lieu of sample for negative controls. The plate was then spun 
down in a centrifuge, covered with a clear film, and analyzed using an ABI 7700 
Sequence Detector® from Applied Biosystems®. The qRT-PCR reaction was set up as 
follows and repeated for 40 cycles: 50°C for 2 minutes, 95°C for 10 minutes, 95°C for 15 
seconds, and 60°C for 1 minute. For analysis of qRT-PCR, Microsoft® Excel® 2011 was 
used to calculate gene expression of the control and treated DBM implants for each 
primer. Values were normalized to non-operated B6,129S7-Rag1tm1/MOM/J mouse femurs 
as a control in order to calculate gene expression fold change compared to control 
femurs. 
 
Statistical Analysis 
 Statistical analysis of the data was performed using GraphPad Prism® 6 and 
Microsoft® Excel® 2011. GraphPad Prism® 6 was used to create graphs comparing 
calculated bone volume from the micro-CT scans of the control and treated DBM 
implants at time points day 8 and day 16. Statistical significance was calculated using a 
multiple comparison t-test via the Holm-Sidak method, where significance was p<0.05. 
  
	  	   19 
RESULTS 
 
X-ray Imaging 
 Mouse femurs were x-rayed immediately after harvest to identify the DBM 
implant on each femur. Day 2 control and experimental mice (treated with TNP-470) 
showed no mineralization of the DBM implant. Day 8 control mice showed a small 
growth of bone on the femur, while day 8 experimental mice showed no observable 
growth. By day 16, the control mice showed a greater growth of bone on the femur. 
However, day 16 experimental mice x-rays showed no mineralization of the DBM 
implant, similar to day 8 experimental mice (Figure 2). 
Figure 2. X-ray imaging of DBM implant. DBM was implanted proximal to mouse 
femurs, and x-rays were taken. (A-E) Arrow indicates site of DBM implantation, while 
circle indicates site of implant with no resulting growth. (A) Day 2 control DBM implant. 
(B) Day 2 DBM implant of mouse treated with TNP-470. (C) Day 8 control DBM 
implant. (D) Day 8 DBM implant of mouse treated with TNP-470. (E) Day 16 control 
DBM implant. (F) Day 16 DBM implant of mouse treated with TNP-470. 
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Micro-CT Analysis 
 Micro-CT analysis was used to both visualize and calculate the bone volume of 
the DBM implants for the day 8 and day 16 time points. Both time points showed a 
significant decrease in bone volume development in the animals treated with TNP-470. 
At the day 8 time point, control animals showed an average bone volume of 0.639 mm3 
(+/- 0.121, n=3), while the experimental mice lacked a measurable amount of bone 
growth. By day 16, the average bone volume for the controls was 1.839 mm3 (+/- 0.344, 
n=5). This was significantly different (p<0.05) when compared to the day 16 
experimental mice, which had an average bone volume of 0.418 mm3 (+/- 0.148, n=5) 
(Figure 3). 
 
Angiogenesis Studies 
 Angiogenesis was detected within the harvested implant by analyzing the relative 
expression of five marker genes known to be associated with endothelial cells and blood 
vessel growth; these were Vegf-a, Vegfr-2, alpha smooth muscle actin (α-Sma), vascular 
endothelial cadherin (VE-cadherin), and platelet endothelial cell adhesion molecule 1 
(Pecam1) (Figure 4). Vegf-a relative gene expression at day 2 for control DBM implants 
showed a mean fold change of 1.630 (+/- 0.288, n=3). There was a significant increase in 
expression for the DBM implants of mice treated with TNP-470 with a fold change 
expression of 25.614 (+/- 6.639, n=5). Similar results were also found in the day 8 
samples, which showed Vegf-a expression of 1.192 (+/- 0.426, n=7) in the controls and 
10.494 (+/- 1.733, n=5) in the TNP-470 treated samples (p<0.005). The trend was similar 
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Figure 3. Micro-CT scans of femur and DBM implant. (A-D) Femur is displayed in 
grey while implant is displayed in yellow. Black arrows point to slices through the 
sample. Individual bone slices show cross-sectional view of bone in white and 
surrounding implant in textured grey. (A) Day 8 Control. (B) Day 8 experimental. (C) 
Day 16 Control. (D) Day 16 Experimental. (E) Bone volume at day 8 and 16 for control 
and TNP-470-treated samples. * = p<0.05, ** = p<0.005. 
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at day 16, though expression was overall decreased. Controls showed a mean fold change 
of 0.537 (+/- 0.069, n=5), and the treated DBM implants demonstrated a significant 
increase in fold change of 1.170 (+/- 0.242, n=5), (Figure 4A). The expression of Vegfr-2 
and α-Sma were also increased with TNP-470 treatment at all three time points. However, 
these differences were not significant (p>0.05) in Vegfr-2 (Figure 4B) and only 
significant at day 8 and day 16 (p<0.05) for α-Sma (Figure 4C). 
 Although there was less VE-cadherin expression in day 2 control DBM implants 
at a mean fold change of 5.143 (+/- 1.644, n=3) than day 2 experimental DBM implants 
at a mean fold change of 99.458 (+/- 43.639, n=5), this difference was not statistically 
significant (p>0.05). However, a significant decrease (p<0.05) was observed in VE-
cadherin expression from 5.949 (+/- 0.675, n=7) in the control samples to 2.882 (+/- 
1.105, n=5) in the experimental samples. At day 16, control implants had a mean fold 
change of 3.239 (+/- 0.733, n=5), and the experimental implants had a mean fold change 
of 17.175 (+/- 3.346, n=5); this difference was significant (p<0.005) (Figure 4D). 
 A statistically significant decrease in Pecam1 expression was observed at all three 
time points (p<0.05). Day 2 control samples had a mean fold change of 1.629 (+/- 0.410, 
n=4), while their corresponding experimental samples had a mean fold change of 0.611 
(+/- 0.193, n=5). At day 8, Pecam1 expression decreased from 1.478 (+/- 0.161, n=7) in 
the control DBM implants to 0.104 (+/- 0.022, n=5) in the treated DBM implants. Day 16 
control samples displayed a mean fold change of 1.476 (+/- 0.250, n=5), while the 
experimental samples showed a mean fold change of 0.055 (+/- 0.006, n=5) (Figure 4E). 
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Stem Cell Studies 
 The stem cell markers chosen for this analysis were Sox2, Nanog, paired related 
homeobox protein 1 (Prx1), and paired box 7 (Pax7). Only the day 2 time point was 
observed for these genes, as day 2 was the earliest time point in our study and is the 
initial step in endochondral ossification. There was no significant difference in Sox2 or 
Figure 4. qRT-PCR analysis of 
angiogenesis genes. Day 2 Control n=3 
and TNP-470-treated n=5. Day 8 Control 
n=7 and TNP-470-treated n=5. Day 16 
Control n=5 and TNP-470-treated n=5. 
(A) Vegf-a (B) Vegfr-2 (C) α-Sma (D) 
VE-cadherin (E) Pecam1. * = p<0.05, ** 
= p<0.005. 
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Prx1 expression between the control and treated DBM implants (p>0.05). Sox2 control 
DBM implants showed a mean fold change of 96.879 (+/- 59.778, n=3), while the 
experimental samples showed a mean fold change of 76.469 (+/- 69.073, n=5) (Figure 
5A). As for Prx1, the control samples had a mean fold change of 25.604 (+/- 4.361, n=4), 
and the treated samples had a mean fold change of 14.585 (+/- 6.520, n=5) (Figure 5B). 
In contrast, substantial decreases in Nanog and Pax7 expression were observed in 
the DBM implants of TNP-470-treated mice. Though the difference in Nanog expression 
was insignificant (p=0.08), there was still a robust difference between a mean fold change 
of 81.194 (+/- 50.568, n=3) in the control samples and a mean fold change of 3.321 (+/- 
1.758, n=5) in the experimental samples (Figure 5C). There was a significant difference 
in Pax7 expression (p<0.005), with a control DBM implant mean fold change of 863.748 
(+/- 213.764, n=4) decreasing to a treated DBM implant mean fold change of 18.870 (+/- 
16.417, n=5) (Figure 5D). 
 
Cartilage Studies 
The expression of these stem cell genes led us to analyze the earliest markers of 
chondrogenesis: Sox9, Sox5, and Sox6. There was expression of Sox9 at day 2 and day 8 
but minimal expression at day 16. There was no significant difference of Sox9 expression 
between the control and experimental samples (p>0.05). Day 2 control samples had a 
mean fold change of 0.578 (+/- 0.251, n=3), and the corresponding experimental samples 
had a mean fold change of 1.486 (+/- 0.516, n=5). Day 8 samples showed an overall 
increase in Sox9 expression, with a mean fold change of 9.435 (+/- 2.693, n=5) for the 
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Figure 5. qRT-PCR analysis of stem cell markers. Day 2 control n=3 and TNP-470-
treated n=5. (A) Sox2 (B) Prx1 (C) Nanog (D) Pax7 * = p<0.05, ** = p<0.005. 
 
control DBM implants and a mean fold change of 7.237 (+/- 2.289, n=5) for the treated 
DBM implants (Figure 8A). Day 16 control samples had a mean fold change of 0.693 
(+/- 0.163, n=5), while the experimental DBM implants had a mean fold change of 4.496 
(+/- 0.801, n=5). This difference was statistically significant (p<0.005) (Figure 6A). 
Sox5 and Sox6 showed decreased expression in the experimental samples at all 
three time points. This difference in Sox5 expression was significant at all three time 
points (p<0.05). Day 2 control samples showed a mean fold change of 2.197 (+/- 0.339, 
n=4), which significantly decreased (p<0.05) to 0.947 (+/- 0.372, n=5) in the 
corresponding experimental samples. Day 8 control samples showed an expression of 
8.888 (+/- 1.297, n=7), and there was less expression in the day 8 experimental samples 
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at 1.092 (+/- 0.206, n=5); this difference was statistically significant (p<0.005). Day 16 
control samples had a mean fold change of 4.247 (+/- 1.219, n=5), and day 16 treated 
samples had a decreased mean fold change of 1.032 (+/- 0.064, n=5); this change was 
also significant (p<0.05) (Figure 6B). The decrease in Sox6 expression between the 
control and TNP-470 treated samples was only significant at day 8 and day 16 (p<0.005) 
(Figure 6C). There was overall less Sox6 expression compared to Sox5 expression in all 
samples. 
Additional genes in the early progression of chondrogenesis include the 
condensation genes N-cadherin and Ncam1. N-cadherin showed decreased expression at 
all three time points, though the decrease at day 2 was not statistically significant 
(p>0.05). Day 2 control samples showed a mean fold change of 0.178 (+/- 0.027, n=4), 
while the corresponding experimental samples showed a mean fold change of 0.105 (+/- 
0.056, n=5). Day 8 control samples had an expression of 0.593 (+/- 0.054, n=7), and the 
experimental samples showed a decreased expression of 0.104 (+/- 0.022, n=5). At day 
16, control DBM implants with a N-cadherin expression of 0.585 (+/- 0.073, n=5) 
decreased to an expression of 0.055 (+/- 0.006, n=5) in the treated DBM implants (Figure 
7A). Ncam1 showed similar results, with decreased expression at all three time points 
that were statistically significant at day 8 (p<0.005) and day 16 (p<0.05) (Figure 7B). 
There was overall greater expression of Ncam1 in all samples compared to N-cadherin. 
The marker genes of Col2a1, Acan, Col10a1, and growth differentiation factor 5 (Gdf5) 
were chosen for observation of the progression of chondrogenesis and for the detection of 
cartilage. Col2a1, Acan, and Col10a1 were minimally, if not at all, expressed in the day 2 
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Figure 6. qRT-PCR analysis of 
cartilage genes. Day 2 Control n=3 and 
TNP-470-treated n=5. Day 8 Control n=7 
and TNP-470-treated n=5. Day 16 
Control n=5 and TNP-470-treated n=5. 
(A) Sox9 (B) Sox5 (C) Sox6 (D) Col2a1 
(E) Acan (F) Col10a1 (G) Gdf5. * = 
p<0.05, ** = p<0.005. 
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Figure 7. qRT-PCR analysis of condensation genes. Day 2 Control n=3 and TNP-470-
treated n=5. Day 8 Control n=7 and TNP-470-treated n=5. Day 16 Control n=5 and TNP-
470-treated n=5. (A) N-cadherin (B) Ncam1. * = p<0.05, ** = p<0.005, else p>0.05 
 
control and TNP-470 treated samples. DBM implants of mice treated with TNP-470 
showed a decrease in expression of these three genes for the day 8 and day 16 time 
points. For Col2a1, day 8 control DBM implants showed a relative gene expression of 
0.269 (+/- 0.157, n=5), while the corresponding day 8 experimental DBM implants 
showed a relative gene expression of 0.014 (+/- 0.009, n=5); this difference was found to 
be insignificant (p>0.05). Day 16 control DBM implants showed a mean fold change of 
0.031 (+/- 0.004, n=5), and the treated DBM implants showed a mean fold change of 
0.006 (+/- 0.003, n=5); this difference was significant (p<0.005) (Figure 6D). Acan and 
Col10a1 showed similar expression trends to Col2a1, though the decreases in expression 
of these genes were found to be only statistically significant at day 2 (Figure 6E & Figure 
6F).  
Gdf5 showed slightly different results than the other cartilage markers because 
there was expression in the day 2 control samples. However, it still showed decreased 
gene expression at all time points. Though results of the day 2 time point were not 
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statistically significant (p>0.05), there was still an observed decrease of expression from 
18.743 (+/- 12.107, n=4) in the control implants to 0.488 (+/- 0.156, n=5) in the 
experimental implants. At day 8, the control samples had a mean fold change of 18.220 
(+/- 3.297, n=7) that decreased to 0.734 (+/- 0.619, n=5) in the treated samples. As for 
day 16, the control DBM implants showed a mean fold change of 17.818 (+/- 4.245, 
n=5), while the experimental DBM implants showed less Gdf5 expression at a mean fold 
change of 0.207 (+/- 0.046, n=5). These decreases were statistically significant (p<0.005) 
(Figure 6G). 
 
Bone Studies 
 qRT-PCR analysis of genes involved in bone formation and remodeling showed a 
decrease in expression in implants following treatment of TNP-470. The following 
primers were chosen for the purpose of this evaluation: Bmp2, Osterix, Osteocalcin, 
Dmp1, and Trap5b.  
Bmp2 showed decreases in expression at all three time points. At day 2, there was 
a mean fold change of 1.889 (+/- 0.695, n=4) in the control samples that decreased to a 
mean fold change of 1.524 (+/- 0.717, n=5) in the TNP-470 treated samples, but this was 
not significant (p>0.05). Day 8 control samples showed a relative gene expression of 
1.100 (+/- 0.116, n=7), while the corresponding experimental samples showed decreased 
gene expression to 0.165 (+/- 0.057, n=5, p<0.005). Day 16 control samples had a mean 
fold change of 1.33 (+/- 0.179, n=5), while day 16 TNP-470 treated samples had a 
smaller mean fold change of 0.304 (+/- 0.059, n=5, p<0.005) (Figure 8A). 
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Osterix, Osteocalcin, and Dmp1 showed similar results in gene expression. All 
three of these markers for bone mineralization showed minimal to no expression at day 2 
and decreased expression in the treated implants at day 8 and day 16. For Osterix, day 8 
control DBM implants showed a mean fold change of 1.198 (+/- 0.753, n=5), and the 
treated DBM implants showed a mean fold change of 0.050 (+/- 0.019, n=5); this 
difference was not significant (p>0.05). A mean fold change of 1.116 (+/- 0.171, n=5) 
was found for day 16 control DBM implants, whereas a mean fold change of 0.016 (+/- 
0.006, n=5) was found for the corresponding DBM implants treated with TNP-470. This 
decrease in expression was found to be significant (p<0.005) (Figure 8B). Results of 
Osteocalcin were similar to those of Osterix in that there was a decrease in expression in 
the TNP-470 treated DBM implants at day 8 and day 16, with statistical significance at 
day 16 (p<0.005) (Figure 8C). As for Dmp1, the mean fold change at day 2 in the control 
DBM implants was 0.0014 (+/- 0.0003, n=3); there was no Dmp1 expression detected in 
the day 2 treated samples (n=5), and this decrease in expression was significant 
(p<0.005). Like Osterix and Osteocalcin, day 8 and day 16 samples showed decreased 
Dmp1 expression in the TNP-470 treated DBM implants, with statistical significance at 
day 16 (p<0.05) (Figure 8D). 
qRT-PCR analysis of Trap5b expression for the detection of bone resorption 
showed a significant increase (p<0.05) at day 2: the control DBM implants showed a 
mean fold change of 0.176 (+/- 0.030, n=4), and the experimental DBM implants showed 
a mean fold change of 0.377 (+/- 0.064, n=5). Day 8 samples showed a significant 
decrease (p<0.005) in expression, with control DBM implants displaying a mean fold 
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change of 4.907 (+/- 0.579, n=7) and treated DBM implants displaying a mean fold 
change of 1.184 (+/- 0.264, n=5). The samples showed a significant decrease (p<0.005) 
in Trap5b expression at day 16 as well: control DBM implants had a mean fold change of 
Figure 8. qRT-PCR analysis of bone 
genes. Day 2 Control n=3 and TNP-470-
treated n=5. Day 8 Control n=7 and TNP-
470-treated n=5. Day 16 Control n=5 and 
TNP-470-treated n=5. (A) Bmp2 (B) 
Osterix (C) Osteocalcin (D) Dmp1 (E) 
Trap5b. * = p<0.05, ** = p<0.005. 
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7.250 (+/- 0.650, n=5) and experimental DBM implants had a mean fold change of 0.605 
(+/- 0.083, n=5) (Figure 8E). 
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DISCUSSION 
  
DBM Implantation as a Model of Bone Formation 
 The control DBM implantation induced ectopic bone formation at the femur, 
shown by x-rays as early as day 8 and continued through day 16. We used qRT-PCR data 
to track endochondral ossification in the control DBM implants. Cartilage markers 
Col2a1, Acan, and Col10a1, and Gdf5, which is responsible for the maintenance of 
cartilage development (Schwaerzer et al., 2012) are readily expressed at day 8. Day 16 
control DBM implants showed presence of the bone markers Bmp2, Osterix, Osteocalcin, 
Dmp1, and Trap5b. qRT-PCR data allowed us to reliably track chondrogenesis and 
mineralization of bone in the DBM control samples. 
 Micro-CT analysis of this provides not only a three-dimensional rendering of the 
implant with relation to the femur but also confirms that the mineralization phase of 
endochondral ossification occurred. There was an increase in bone volume between the 
day 8 and day 16 time points, which is consistent with the process of endochondral 
ossification, since day 8 is a time point at which the chondrogenic stage tends to occur 
and day 16 is a time point at which mineralization is well under way (unpublished data). 
 
Evidence of Angiogenesis Inhibition 
The inhibition of angiogenesis was evaluated using qRT-PCR analysis of Vegf-a, 
Vegfr-2, α-Sma, VE-cadherin, and Pecam1. As mentioned earlier, VEGF-A and VEGFR-
2 play integral roles as ligand and receptor, respectfully, in the tyrosine kinase pathway of 
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endothelial cell formation (Holmes et al., 2007) and are thus early markers of endothelial 
cell growth. Although Vegfr-2 showed increased expression at all three time points, the 
findings were not statistically significant. There was a significant increase in Vegf-a at 
day 2 and day 8 in the treated sample. In control mice, a small increase in Vegf-a 
expression would recruit vessel formation as a means to support bone formation in the 
DBM implant. Increased expression in the control implants is also consistent with the 
finding that vessel formation is induced prior to the onset of chondrogenesis in 
heterotopic ossification driven by BMP2 (Dilling et al., 2010), since DBM utilizes the 
properties of BMP2 in de novo bone formation. However, in the TNP-470 injected mice, 
VEGF-A ligand secretion could plausibly increase to compensate for the lack of 
endothelial cell proliferation and resulting vessel formation; this reasoning is compatible 
with TNP-470’s mechanism of action as an angiogenesis inhibitor, which acts by 
suspending the endothelial cell cycle, thus preventing cell proliferation and 
differentiation (“NCI Drug Dictionary”, n.d., para. 1). 
α-Sma is a marker of myofibroblasts, whose differentiation leads to the synthesis 
of smooth muscle that makes up blood vessels (Abdalla et al., 2013). α-Sma expression 
was also greater in the TNP-470-treated samples at all three time points, with the change 
being significant at the day 8 and day 16 time points. The α-Sma expression mirrors the 
Vegf-a data in that the lack of vessel formation due to cell cycle arrest causes an increase 
in ligand, receptor, and vessel components as a compensatory mechanism.   
VE-cadherin and Pecam1 are later markers of endothelial formation. The VE-
cadherin gene regulates endothelial permeability and is expressed by endothelial cells 
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(Zeng et al., 2012), while Pecam1 is a marker for endothelial cell adhesion (Kellermair et 
al., 2013). VE-cadherin only showed a significant decrease in expression at day 8. 
Although greater expression of VE-cadherin occurred in the experimental sample 
compared to its corresponding control at the day 16 time point, it is possible this is an 
effect of the anti-angiogenic agent. Previous studies have found that up-regulation of VE-
cadherin is required to prevent the disassociation of nascent blood vessels (Crosby et al., 
2005); thus, it is possible that the increased VE-cadherin was a product of the 
physiological attempt to increase vascularization to the DBM implant in the presence of 
an angiogenesis inhibitor. 
Only Pecam1 showed significant decrease in expression in the experimental 
animals at all three time points. PECAM1 is found in the intercellular junctions between 
endothelial cells, and its lack of expression would correlate with leaky or incomplete 
vessel formation. Thus, despite the inconsistent results with other angiogenic markers, 
this may substantiate TNP-470’s role in preventing angiogenesis in our mice. However, 
we are currently performing perfusion studies to verify these claims with increased rigor 
using micro-CT imaging of vessel formation. 
 
TNP-470 Hinders Bone Mineralization 
 The x-ray images of the DBM implants post-treatment showed a lack of ectopic 
bone mineralization compared to the non-treated DBM implants through time. However, 
the difference appeared to be most robust at day 16. This was supported by the micro-CT 
images and quantified bone volumes of the ectopic bone. 
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A closer look at the qRT-PCR data supports these x-ray and micro-CT findings. 
Expression of Bmp2, which promotes osteoblast differentiation (Pietrzak et al., 2005), 
was significantly decreased at day 8 and day 16. Since Osterix (Lee et al., 2003) and 
Osteocalcin (Ducy & Karsenty, 1995) are markers for osteoblasts, Trap5b is an osteoclast 
marker (Henriksen et al., 2007), and Dmp1 is a gene that is expressed by osteocytes 
(Kashima et al., 2013), together, the presence of these genes would implicate the 
occurrence of mineralization and bone turnover. By day 16, a conservative time point for 
the mineralization of the DBM implant undergoing endochondral ossification and for the 
completion of chondrogenesis (unpublished data), all four genes display significantly less 
expression in the DBM implants of mice treated with TNP-470, if any. Thus, bone 
mineralization is vastly inhibited by the blockage of angiogenesis. 
 
Diminished Chondrogenesis Follows Inhibition of Angiogenesis 
 The observed decrease in relative gene expression for the early- to late-cartilage 
markers (Col2a1, Acan, and Col10a1) to almost zero in the TNP-470-treated samples 
supports the claim that chondrogenesis did not progress. Unexpectedly, analysis of an 
earlier stage in endochondral ossification yielded similar results. N-cadherin and Ncam1, 
which are considered early markers of condensation, showed significant decrease in 
expression in the mice treated with the anti-angiogenic agent. Since the differences in 
mean fold change were not as substantial as those of the chondrogenesis markers, such 
results encouraged further analysis of the earliest stages of chondrogenesis and of 
pluripotent stem cells. 
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Angiogenesis is Crucial to the Earliest Endochondral Ossification Stages 
 Once we learned that mineralization, condensation, and chondrogenesis are all 
hindered by the inhibition of angiogenesis, we delved deeper into chondrogenesis. Our 
goal was to isolate the critical point where blood vessels, and the components they 
provide, are necessary. We analyzed markers of mesenchymal stem cells such as Sox2, 
Nanog, Prx1, and Pax7 in day 2 control and treated samples. Sox2 and Nanog are 
transcription factors involved in the pluripotency of embryonic stem cells (Takahashi & 
Yamanaka, 2006) that have been shown, in some instances, to work together to mediate 
embryonic stem cell self-renewal (Gagliardi et al., 2013). Prx1 works with Sox2 to 
maintain adult neural stem cells (Shimozaki et al., 2013) and plays an important role in 
limb development (Higuchi et al., 2013). Muscle satellite cells express Pax7, which is 
believed to be a requirement for regenerative myogenesis (Maltzahn et al., 2013). 
 The presence of mesenchymal stem cells was confirmed in all control DBM 
implants, and Sox2 and Prx1 remained in the experimental DBM implants despite 
treatment with TNP-470. Though there appeared to be considerably less Nanog 
expression in the treated samples, this difference was not statistically significant. Nanog 
has been linked to Vegfr-2 transcription and thus angiogenesis (Kohler et al., 2010), so it 
is conceivable that TNP-470 perhaps had an indirect inhibitory effect on Nanog. The 
decreased Pax7 expression may be explained as an effect of TNP-470 as well, since 
muscle is believed to play a supportive role in providing vascularization to sites of new 
bone formation (Liu et al., 2010); therefore, the inhibition of angiogenesis may eliminate 
the need for muscle formation and, surely, muscle satellite cells. Since TNP-470 did not 
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affect Sox2 and Prx1, it is probable that the lack of bone formation is not due to the 
inability to recruit mesenchymal stem cells in the earliest stage of cartilage formation. 
 Previous studies have shown that BMP signaling, which is utilized by DBM for 
bone formation (Pietrzak et al., 2005), and the Sox genes work together to promote 
cartilage differentiation of the limbs (Chimal-Monroy et al., 2003). Analysis of these 
earliest markers of endochondral ossification yielded interesting results. There was no 
significant difference in Sox9 expression between the control and experimental samples 
at the first two time points and a significant increase in Sox9 expression at the day 16 
time point. The Sox9 day 2 and day 8 results were expected because Sox9 is needed for 
stem cells to commit to differentiation into chondrocytes and is often inactivated after 
condensation. However, there is increased Sox9 expression in the treated animals at day 
16, when the chondrogenic phase of endochondral ossification is expected to be 
complete. Increased Sox9 expression in the day 16 experimental animals but a significant 
decrease in later cartilage genes suggests that there is commitment to chondrogenesis by 
this time point but no completion of chondrogenesis with TNP-470 treatment.  
Sox9 is also required for activation of the subsequent Sox5 and Sox6 transcription 
factors in chondrogenesis (Akiyama et al., 2002). TNP-470 treatment affected Sox5 and 
Sox6 expression, with decreases in mean fold change at all three time points in both 
genes. Therefore, less expression of Sox5 and Sox6 in the samples treated with anti-
angiogenic agent suggests that angiogenesis plays a role in endochondral ossification in 
the earliest stages of chondrogenesis, even before condensation. 
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Conclusions & Future Directions  
The above results suggest that the DBM implantation is a successful model for de 
novo bone formation and that angiogenesis is needed for chondrogenesis, specifically in 
the condensation and progression of endochondral bone formation.  
This study is fundamental to determining the function of angiogenesis in early 
endochondral ossification. It is currently accepted that vascularization is needed in the 
later chondrogenic stage of endochondral ossification and for the mineralization of bone, 
but its exact role in early the periods of chondrogenic differentiation remains unknown. 
Our investigation showed that angiogenesis is necessary for cartilage formation and 
maintenance, which is supported by existing evidence of the necessity of VEGF-A for 
chondrocyte survival during bone development (Zelzer et al., 2003). Beyond this, our 
findings also reveal reasonable justification for angiogenesis to occur in the earliest 
stages of endochondral bone formation, namely during the period after stem cell 
recruitment of the chondrogenic linage based on Sox9 expression but preceding further 
progression based on lack of Sox5 and Sox6 activity. This novel claim opposes more 
recent theories that place VEGF expression and regulation, and thus angiogenesis, in 
condensed mesenchyme as the initial step in vascularization of limb development 
(Eshkar-Oren et al., 2009). Successful further experimentation utilizing micro-CT 
analysis to confirm inhibition of angiogenesis and modeling the process in vitro to 
perform gene silencing will further validate our findings. 
 A better understanding of the mechanism by which endochondral ossification 
occurs allows us to improve treatments of skeletal impairments. Specific advances in 
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research concerning cartilage development progresses the field of cartilage regeneration 
and cartilage replacement therapy. 
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